Targeting claudins in cancer.

Targeting claudins offers a promising new approach, with zolbetuximab becoming the first FDA-approved CLDN-18.2-targeted antibody for gastric cancer treatment.

• Why it matters: Epithelial-derived cancers are highly heterogeneous and resistant to existing therapies, creating a critical need for novel targeted treatments that can improve patient outcomes.
• What they did: Researchers reviewed the development of claudin-targeting therapeutics, focusing on key advances, challenges, and the clinical progress of molecules like zolbetuximab, which specifically targets CLDN-18.2.
• The result: This progress demonstrates the therapeutic potential of claudins, paving the way for expanded treatment options and encouraging further research into their role as cancer targets.